北京诺禾致源科技股份公司 独立董事提名人声明与承诺 提名人北京诺禾致源科技股份有限公司董事会,现提名王天凡为 北京诺禾致源科技股份有限公司第四届董事会独立董事候选人,并已 充分了解被提名人职业、学历、职称、详细的工作经历、全部兼职、 有无重大失信等不良记录等情况。被提名人已书面同意出任北京诺禾 致源科技股份有限公司第四届董事会独立董事候选人(参见该独立董 事候选人声明)。提名人认为,被提名人具备独立董事任职资格,与 北京诺禾致源科技股份有限公司之间不存在任何影响其独立性的关 系,具体声明并承诺如下: 一、被提名人具备上市公司运作的基本知识,熟悉相关法律、行 政法规、规章及其他规范性文件,具有五年以上法律、经济、会计、 财务、管理等履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训证明 材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要求: (一)《中华人民共和国公司法》等关于董事任职资格的规定; (二)《中华人民共和国公务员法》关于公务员兼任职务的规定 (如适用); (三)中国证监会《上市公司独立董事管理办法》、上海证券交 易所自律监管规则以及公司章程有关独立 ...

公司代码：688315 公司简称：诺禾致源 北京诺禾致源科技股份有限公司 2024 年度内部控制评价报告 北京诺禾致源科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的 ...

一、 召开会议的基本情况 （一） 股东大会类型和届次 证券代码：688315 证券简称：诺禾致源 公告编号：2025-020 北京诺禾致源科技股份有限公司 关于召开 2024 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2024 年年度股东大会 召开日期时间：2025 年 5 月 7 日 13 点 30 分 召开地点：北京市朝阳区酒仙桥北路甲 10 号院 301 号楼 101 栋诺禾致源大 厦一楼多功能厅 网络投票起止时间：自 2025 年 5 月 7 日 至 2025 年 5 月 7 日 股东大会召开日期：2025年5月7日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 采用上海证券交易所网络投票系统，通过交易系 ...

证券代码：688315 证券简称：诺禾致源 公告编号：2025-022 北京诺禾致源科技股份有限公司 第三届监事会第二十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京诺禾致源科技股份有限公司（以下简称"公司"）第三届监事会第二十次 会议于 2025 年 4 月 14 日召开，公司已于 2025 年 4 月 4 日以邮件、电话等方式 向公司全体监事发出了会议通知。本次会议由监事会主席李兴园女士召集并主持， 应参加本次监事会会议的监事 3 人，实际参加本次监事会会议的监事 3 人。会议 符合《中华人民共和国公司法》和《北京诺禾致源科技股份有限公司章程》（以 下简称"《公司章程》"）及有关法律法规要求。会议审议并通过了如下议案： 一、审议并通过了《关于公司 2024 年年度监事会工作报告的议案》 根据有关法律法规的相关规定，监事会就公司 2024 年年度监事会的运转情 况拟订了《2024 年年度监事会工作报告》。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 本议案尚需提交股东大会审议。 二、审议并 ...

证券代码：688315 证券简称：诺禾致源 公告编号：2025-021 根据有关法律法规的有关规定，总经理就公司 2024 年年度公司生产经营情 况拟订了《2024 年年度总经理工作报告》。 北京诺禾致源科技股份有限公司 第三届董事会第二十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京诺禾致源科技股份有限公司（以下简称"公司"）第三届董事会第二十二 次会议于 2025 年 4 月 14 日召开，公司已于 2025 年 4 月 4 日以邮件、电话等方 式向公司全体董事发出了会议通知。会议由董事长李瑞强先生召集并主持，应参 加本次董事会会议的董事 5 人，实际参加本次董事会会议的董事 5 人。会议符合 《中华人民共和国公司法》（以下简称"《公司法》"）和《北京诺禾致源科技股份 有限公司章程》（以下简称"《公司章程》"）及有关法律法规要求。会议审议并通 过了如下议案： 一、审议并通过了《关于公司 2024 年年度董事会工作报告的议案》 根据有关法律法规的相关规定，董事会就公司 2024 年年度董事会的运转 ...

证券代码：688315 证券简称：诺禾致源 公告编号：2025-013 北京诺禾致源科技股份有限公司 2024 年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配方案内容 （一）利润分配方案具体内容 经立信会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，公 司母公司期末可供分配利润为人民币 631,130,982.16 元。2024 年度，公司合并利 润表归属于上市公司股东的净利润为人民币 196,788,496.06 元。经公司第三届董 事会第二十二次会议决议，公司 2024 年度拟以实施权益分派股权登记日登记的 总股本扣减公司回购专用证券账户中股份数为基数分配利润。本次利润分配方案 如下： 1 公司拟向全体股东每股派发现金红利 0.05 元（含税）。截至 2024 年 12 月 31 日，公司总股本 416,200,000 股，扣减回购专用证券账户中股份数 11,141,468 股，可参与利润分配股数 405,058,532 股，以此计算合计拟 ...

Financial Performance - Novogene reported a revenue of RMB 1.2 billion for the last fiscal year, representing a year-over-year growth of 25%[19]. - The company's operating revenue for 2024 reached ¥2,111,319,193.13, representing a year-on-year increase of 5.45% compared to ¥2,002,107,701.39 in 2023[27]. - Net profit attributable to shareholders for 2024 was ¥196,788,496.06, up 10.52% from ¥178,059,764.27 in 2023, driven by increased operating revenue[30]. - The basic and diluted earnings per share for 2024 were both ¥0.48, reflecting a 9.09% increase from ¥0.44 in 2023[29]. - The company's cash flow from operating activities for 2024 was ¥385,538,071.76, a 15.36% increase from ¥334,197,677.56 in 2023[27]. - The total assets at the end of 2024 were ¥3,636,977,990.07, a 1.18% increase from ¥3,594,420,954.11 at the end of 2023[28]. - The net assets attributable to shareholders increased to ¥2,489,835,892.67, up 1.32% from ¥2,457,457,998.48 in 2023[28]. - The company's R&D expenditure as a percentage of operating revenue was 6.38% in 2024, up from 6.20% in 2023[29]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥170,759,798.53, a 21.98% increase from ¥139,987,341.83 in 2023[30]. Dividend and Share Capital - The company plans to distribute a cash dividend of RMB 0.05 per share (including tax), totaling approximately RMB 20,252,926.60, which represents 10.29% of the net profit attributable to shareholders in the consolidated financial statements for 2024[7]. - As of December 31, 2024, the total share capital of the company is 416,200,000 shares, after deducting 11,141,468 shares held in the repurchase special securities account[7]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the 2024 fiscal year[7]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[6]. - The company's board of directors and supervisory board members have ensured the accuracy and completeness of the annual report[3]. - The company has not reported any instances where more than half of the directors could not guarantee the authenticity of the annual report[10]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[10]. - The company has not violated any decision-making procedures in providing guarantees[10]. Market and Growth Strategy - Novogene anticipates a revenue growth of 20% for the upcoming fiscal year, projecting revenues to reach RMB 1.44 billion[19]. - The company is investing RMB 200 million in R&D for new genomic technologies and products in the next year[19]. - Novogene plans to expand its market presence in Europe and North America, targeting a 30% increase in international sales[19]. - The company has successfully completed the acquisition of a smaller biotech firm, enhancing its capabilities in next-generation sequencing[19]. - The company is focusing on developing non-invasive prenatal testing solutions, which are expected to contribute significantly to future revenues[19]. Customer and Client Base - The company has expanded its user base to over 10,000 active clients, an increase of 15% compared to the previous year[19]. - Novogene's customer satisfaction rate has reached 90%, reflecting improvements in service delivery and product quality[19]. - The company serves nearly 7,300 clients globally, covering approximately 90 countries and regions, with a strong presence in North America, Europe, and Southeast Asia[50]. Research and Development - The company has developed a comprehensive multi-omics service system, including technologies for genomics, transcriptomics, and proteomics[43]. - The company is actively exploring clinical applications of long-read sequencing and methylation sequencing technologies[46]. - The company has published or been cited in over 30,467 SCI articles with a cumulative impact factor of 208,245.37 and holds 79 invention patents and 495 software copyrights as of December 31, 2024[49]. - The company has established collaborations with multiple top-tier hospitals for its pathogen metagenomics high-throughput detection products[47]. - The company has automated the library construction process and developed over a hundred personalized extraction methods for non-standard samples[57]. Technology and Innovation - The company has introduced multiple new sequencing systems, including Illumina's NovaSeq X Plus and PacBio's Revio, enhancing sequencing throughput and meeting the latest sequencing demands[80]. - The company is actively exploring AI technology applications, with its AI bioinformatics expert "Novi" already available for free to clients, providing standardized and efficient bioinformatics analysis solutions[81]. - The company has developed a unique competitive advantage in several advanced sequencing technologies, including de novo sequencing and single-cell sequencing[118]. - The company aims to enhance its product services and technology platforms, focusing on various business lines including livestock, animals, plants, crops, microorganisms, cancer, and single-cell research to better meet customer needs[182]. Risks and Challenges - The company faces risks related to a lack of clinical application qualifications and a single product line, which could impact its competitive edge if new products are not developed timely[120]. - The company is exposed to intense market competition, which may lead to significant price declines and affect overall profitability if operational strategies are not adjusted[123]. - The company relies heavily on a few suppliers for sequencing instruments and reagents, which poses a risk; it plans to diversify its supplier base to mitigate this dependency[124]. Corporate Governance - The company has improved its corporate governance structure in compliance with relevant laws and regulations, ensuring transparency and accountability in operations[191]. - The board of directors actively participates in meetings and committees, ensuring the protection of shareholders' rights and interests[192]. - The company has established a fair and transparent performance evaluation system to attract and retain talent, promoting sustainable human resource development[189].

Financial Performance - The company's revenue for Q1 2025 was CNY 502,005,677.53, representing a 7.16% increase compared to CNY 468,475,325.62 in the same period last year[3] - Net profit attributable to shareholders was CNY 33,875,583.34, up 24.02% from CNY 27,315,351.75 year-over-year[3] - The basic earnings per share rose to CNY 0.08, a 14.29% increase from CNY 0.07 in the prior year[3] - Operating profit for Q1 2025 was RMB 38,979,110.09, compared to RMB 33,132,260.39 in Q1 2024, indicating a growth of 17.4%[14] - The net profit for Q1 2025 was CNY 36,069,339.72, an increase of 25.5% compared to CNY 28,754,862.43 in Q1 2024[15] - The total comprehensive income for Q1 2025 reached CNY 44,809,854.58, up 87.8% from CNY 23,842,215.83 in Q1 2024[15] - Basic and diluted earnings per share for Q1 2025 were both CNY 0.08, compared to CNY 0.07 in Q1 2024, reflecting a 14.3% increase[16] Research and Development - R&D expenses totaled CNY 29,464,412.16, an increase of 33.72% from CNY 22,034,279.90 in the previous year, accounting for 5.87% of revenue[4] - Research and development expenses for Q1 2025 were RMB 28,466,477.75, up from RMB 21,378,735.83 in Q1 2024, indicating a year-over-year increase of 33.0%[14] - Research and development expenses increased significantly to CNY 23,150,884.01 in Q1 2025, compared to CNY 14,955,959.11 in Q1 2024, marking a rise of 54.56%[22] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -147,278,064.55, compared to CNY -108,479,469.28 in the same period last year[3] - Cash inflow from operating activities in Q1 2025 was CNY 442,719,320.52, compared to CNY 401,224,877.38 in Q1 2024, marking a growth of 10.3%[17] - The net cash flow from investing activities for Q1 2025 was CNY 200,057,471.63, a significant recovery from a negative CNY 57,580,146.82 in Q1 2024[18] - The company reported a net cash outflow from financing activities of CNY 3,821,247.76 in Q1 2025, compared to a larger outflow of CNY 51,717,442.10 in Q1 2024[18] - The cash and cash equivalents increased from CNY 67,496,386.38 to CNY 163,367,400.01, showing a growth of 142.43%[20] - The ending balance of cash and cash equivalents was $67,396,386.38 in Q1 2025, down from $249,121,587.45 in Q1 2024[26] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,637,738,270.37, a slight increase of 0.02% from CNY 3,636,977,990.07 at the end of the previous year[4] - Total liabilities decreased to RMB 1,079,854,783.92 as of March 31, 2025, from RMB 1,123,904,358.20 at the end of 2024, a reduction of 3.9%[12] - Shareholders' equity increased to RMB 2,557,883,486.45 as of March 31, 2025, compared to RMB 2,513,073,631.87 at the end of 2024, marking a growth of 1.8%[12] - The company's total assets increased from CNY 2,658,057,108.36 to CNY 2,771,614,940.75, reflecting a growth of approximately 4.26%[21] - The company's total liabilities rose from CNY 498,681,691.01 to CNY 626,535,556.98, indicating an increase of approximately 25.66%[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,593[7] - The largest shareholder, Li Ruiqiang, holds 51.61% of the shares, totaling 214,810,148 shares[7]

诺禾致源公告，2024年营业收入21.11亿元，同比增长5.45%。归属于上市公司股东的净利润1.97亿元， 同比增长10.52%。公司拟向全体股东每股派发现金红利0.05元(含税)，合计拟派发现金红利人民币 2025.29万元(含税)。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688315 证券简称：诺禾致源 公告编号：2025-009 北京诺禾致源科技股份有限公司 关于会计估计变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 根据《企业会计准则第28号一一会计政策、会计估计变更和差错更正》的相关规定，北京诺禾致源科 技股份有限公司（以下简称"公司"）本次会计估计变更采用未来适用法进行相应的处理，无需对公司已 披露的财务报表进行追溯调整，对以往各年度财务状况和经营成果不会产生影响。 ● 本次会计估计变更自2025年1月1日起开始执行。 一、本次固定资产残值率会计估计变更情况概述 （一）会计估计变更原因 公司作为基因测序行业中游服务商，其测序主要生产设备的残值率原按行业惯例设定为5%。近年来， 随着国产测序设备技术突破及海外厂商加速布局，上游设备供给显著增加，服役期满的设备处置价格持 续下行。这一结构性变化使得设备处置时的实际残值率与会计估计残值率产生偏离。 根据公司近五年设备全周期运营数据，测序主要生产设备 ...